We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Low Compliance Rates Hinder PC Active Surveillance

By HospiMedica International staff writers
Posted on 17 Jun 2019
Print article
A new study claims active surveillance of prostate cancer is rarely successful (Photo courtesy of iStockPhoto).
A new study claims active surveillance of prostate cancer is rarely successful (Photo courtesy of iStockPhoto).
Only one in six men who choose active surveillance (AS) instead of immediate treatment for early stage prostate cancer (PC) actually undergo monitoring, claims a new study.

Researchers at the University of North Carolina (UNC, Chapel Hill, USA) conducted a population-based cohort study involving 346 men with newly diagnosed low- or intermediate-risk PC between 2011 and 2013 who pursued AS. Medical records and patient-reported outcomes, including prostate cancer anxiety (PCA) and prostate cancer decision regret (PCDR), were collected prospectively. Adherence monitoring was assessed per contemporary guidelines, which recommend prostate-specific antigen (PSA) testing every 3–6 months and prostate biopsy within 18 months of initial diagnosis.

The results revealed that 58% of patients received adequate PSA testing and 45% underwent prostate biopsy; overall, 32% of patients received guideline-adherent monitoring. Urology follow-up during the first year was 97%, but dropped to 67% in year two. In addition, the researchers found that within the first two years, 16% of patients converted to treatment, dropping the AS group to just 15% of the cohort. PCA scores and younger age were significantly associated with conversion, and 94% expressed no regret. The study was presented at the American Society of Clinical Oncology (ASCO) annual meeting, held during June 2019 in Chicago (IL, USA).

“What we thought upfront was that adherence to monitoring would not be perfect, but what we found was that adherence to monitoring was only about 15%. If that's the case, it raises the question as to whether AS is a good option for patients and whether it's safe,” said senior author Ronald Chen, MD, MPH. “I want to emphasize our message with this study is not to discourage AS, as we recognize that patients with low-risk prostate cancer are being over-treated. If we are going to offer it, we must make sure that patients are reminded about their appointments, that someone is tracking the fact that they are getting the monitoring they need.”

Current standard of care for men with low-risk prostate cancer is AS, which involves monitoring of PSA levels, digital rectal exams, or prostate biopsies. As radical therapy, which involves surgically removing or irradiating the whole prostate, has significant long-term side effects, including erectile dysfunction and incontinence, it is only used to treat high-risk cancers.

Related Links:
University of North Carolina

Print article


Copyright © 2000-2020 Globetech Media. All rights reserved.